Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study
Abstract
Objective: This study was conducted to see the effects of berberine, metformin, and myoinositol in women with polycystic ovary syndrome (PCOS). Materials and Methods: Subjects were randomly assigned via computer-generated randomization to one of the three treatment groups. Group 1 received berberine hydrochloride 500 mg twice daily, group 2 received metformin hydrochloride 500 mg twice daily, and group 3 received myoinositol 1000 mg twice daily to compare clinically (mean weight, waist circumference, waist-to-hip ratio, and body mass index), metabolic (fasting blood sugar, serum fasting insulin, fasting blood sugar/serum fasting insulin [FBS/FI]), hormonal effects (serum total testosterone [TT], serum sex hormone-binding globulin [SHBG] and free androgen index) together with the lipid profile (total cholesterol, serum triglyceride, serum low-density lipoprotein [LDL], very-low-density lipoprotein [VLDL], serum high-density lipoprotein [HDL]) in patients receiving metformin, berberine, and myoinositol before and after three months of treatment. Results: Weight, BMI, waist circumference, waist-hip ratio, FBS, FI and fasting glucose/insulin ratio, total testosterone, free androgen index (FAI), SHBG, total cholesterol, triglycerides, LDL, VLDL, and HDL showed significant differences in three groups after three months of treatment (p<0.0001). Between the three groups, berberine showed greater differences in clinical, hormonal, and lipid parameters compared to metformin and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.